Immunomodulatory effects of a set of amygdalin analogues on human keratinocyte cells

Experimental Dermatology

Volumn 14, Issue 11, 2005, Pages 854-859

  Baroni, A ^a   Paoletti, I ^a   Greco, R ^a   Satriano, R A ^a   Ruocco, E ^a   Tufano, Maria Antonietta ^a   Perez, J J ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

Immunomodulation; Keratinocytes; Peptide T; Peptidomimetics; Psoriasis

Indexed keywords

AMYGDALIN; AMYGDALIN DERIVATIVE; CD51 ANTIGEN; CYANIDE; HEAT SHOCK PROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; PEPTIDE DERIVATIVE; PEPTIDE T; SVT 03016; SVT 03017; SVT 03018; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; KERATINOCYTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PSORIASIS; UPREGULATION; WESTERN BLOTTING;

AMYGDALIN; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOLOGIC FACTORS; INTEGRIN ALPHAV; INTERCELLULAR ADHESION MOLECULE-1; KERATINOCYTES; PEPTIDE T; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 27744533629     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2005.00368.x     Document Type: Article

References (21)

1. Raychaudhuri S P, Farber E M, Raychaudhuri S K. Immunomodulatory effects of peptide T on Th1/Th2 cytokine. Int J Immunopharmacol 1999: 21: 609-615.
2. Farber E F, Cohen E N, Trozak D J, Wilkinson D I. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol 1991: 25: 658-664.
3. Talme T, Rozell B L, Sundquist K G et al. Histopathological and immunohistochemical changes in psoriatic skin during peptide T treatment. Arch Dermatol Res 1995: 287: 553-557.
4. Bjerke J R, Hawkenes G, Livden J K et al. Activated T lymphocytes, interferon and retrovirus-like particles in psoriatic lesions. Arch Dermatol 1983: 119: 955-956.
5. Johansson O, Hilliges M, Talme T et al. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment. Acta Derm Venereol 1994: 74: 106-109.
6. Raychaudhuri S K, Raychaudhuri S P, Faber E M. Anti-chemotactic activities of peptide T: a possible mechanism of actions for its therapeutic effects on psoriasis. Int J Immunopharmacol 1998: 20: 661-667.
7. Tufano M A, Greco R, Paoletti I, Donnarumma G, Canozo N, Baroni A. Immunomodulatory effects of peptide T on human keratinocyte cells. Br J Dermatol 2002: 147: 663-669.
8. Shipley G D, Pittelkow M R, Willie J J Jr et al. Reversible inhibition of normal human prokeratinocyte proliferation by type β transforming growth factor - growth inhibitor in serum-free medium. Cancer Res 1986: 46: 2068-2071.
9. Reiss M, Sartorelli A C. Regulation of growth and differentiation of human keratinocytes by type β transforming growth factor and epidermal growth factor. Cancer Res 1987: 47: 6705-6709.
10. Welch W J. Mammalian stress response: cell physiology, structure/function stress proteins, and implications for medicine and disease. Physiol Rev 1992: 72: 1063-1081.
11. Llorens O, Filizola M, Spisani S, Marastoni M, Herranz C, Perez J J. Amygdalin binds to the CD4 receptor as suggested from molecular modelling studies. Bioorg Med Chem Lett 1998: 8: 781-786.
12. Araya E, Rodríguez A, Rubio A et al. Synthesis and evaluation of diverse analogs of amygdalin as potential peptidomimetics of peptide T. Bioorg Med Chem Lett 2005: 15: 1493-1496.
13. Boyce S T, Ham R G. Calcium regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum free serial culture. J Invest Dermatol 1983: 81: 33-40.
14. Bradford M. A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein binding. Anal Biochem 1976: 72: 248-256.
15. Kormeili T, Lowe N J, Yamauchi Y. Psoriasis: immunopathogenesis and evolvine immunomodulators and systemic therapies; U. S experiences. Br J Dermatol 2004: 151: 3-15.
16. Tutrone D W, Kagen M H, Barbagallo J, Weinberg J M. Biologic therapy of psoriasis: a brief history, I. Cutis 2001: 68: 331-336.
17. Asadullah K, Sabat R, Wiese A et al. Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res 1999: 291: 628-636.
18. Asadullah K, Docke W D, Ebeling M et al. Interleukin-10 treatment psoriasis. Arch Dermatol 1999: 135: 187-192.
19. Asadullah K, Sabat R, Wiese A et al. Interleukin-10 in cutaneous disorders: implication for its pathophysiological importance and therapeutic use. Arch Dermatol 1999: 291: 628-636.
20. Seifert M, Gruenberg B H, Sabat R et al. Keratinocyte unresponsiveness towards interleukin-10: lack of specific binding due to deficient IL-10 receptor 1 expression. Exp Dermatol 2003: 12: 137-144.
21. Dustin M L, Singer K H, Tuck D T, Springer T A. Adhesion of T lymphoblast to epidermal keratinocytes is regulated by interferon-γ and is mediated by intercellular adhesion molecule-1 (ICAM-1). J Exp Med 1988: 167: 13-23.